Display options
Cite
Sandler HM, Pienta KJ. Rationale for the Radiation Therapy Oncology Group Study RTOG P-0014. Rev Urol. 2003;5:S45-51
Sandler, H. M., & Pienta, K. J. (2003). Rationale for the Radiation Therapy Oncology Group Study RTOG P-0014. Reviews in urology, 5S45-51.
Sandler, Howard M, and Pienta, Kenneth J. "Rationale for the Radiation Therapy Oncology Group Study RTOG P-0014." Reviews in urology vol. 5 (2003): S45-51.
Sandler HM, Pienta KJ. Rationale for the Radiation Therapy Oncology Group Study RTOG P-0014. Rev Urol. 2003;5:S45-51. PMID: 16985950; PMCID: PMC1502341.
Copy Download .nbib Format: NLM
Share it on

Rev Urol. 2003;5:S45-51.

Rationale for the Radiation Therapy Oncology Group Study RTOG P-0014.

Reviews in urology

Howard M Sandler, Kenneth J Pienta

PMID: 16985950 PMCID: PMC1502341

Abstract

Chemotherapy currently has an established role in the treatment of hormonere-fractory prostate cancer. There is strong evidence that combined-modality treatment, using androgen ablation in addition to radiotherapy, provides a benefit above and beyond radiotherapy alone in patients with a poor prognosis, perhaps due to the effect of androgen ablation on subclinical distant disease. Several clinical trials currently under way are investigating whether the addition of chemotherapy with known efficacy in the hormone-refractory setting can provide a survival advantage when used adjuvantly.

References

  1. N Engl J Med. 1998 Oct 8;339(15):1036-42 - PubMed
  2. Ann Oncol. 1999 Jan;10(1):33-8 - PubMed
  3. J Clin Oncol. 2001 May 1;19(9):2509-16 - PubMed
  4. J Clin Oncol. 1999 Oct;17(10):3160-6 - PubMed
  5. Urology. 1995 Aug;46(2):142-8 - PubMed
  6. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10560-4 - PubMed
  7. CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 - PubMed
  8. Drugs Aging. 1995 Jul;7(1):49-74 - PubMed
  9. Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-72-S15-77 - PubMed
  10. Cancer. 2002 Mar 1;94(5):1457-65 - PubMed
  11. JAMA. 1999 May 5;281(17):1591-7 - PubMed
  12. J Clin Oncol. 1999 Aug;17(8):2506-13 - PubMed
  13. J Clin Oncol. 2003 Feb 1;21(3):483-9 - PubMed
  14. Urology. 1996 Jul;48(1):164-70 - PubMed
  15. J Clin Oncol. 1998 May;16(5):1835-43 - PubMed
  16. Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):937-46 - PubMed
  17. J Clin Oncol. 2002 Aug 15;20(16):3376-85 - PubMed
  18. J Urol. 2003 Feb;169(2):517-23 - PubMed
  19. Clin Cancer Res. 1997 Dec;3(12 Pt 1):2371-6 - PubMed
  20. J Clin Oncol. 1996 Jun;14(6):1756-64 - PubMed
  21. N Engl J Med. 1999 Dec 9;341(24):1781-8 - PubMed
  22. J Clin Oncol. 2000 Oct 1;18(19):3352-9 - PubMed
  23. Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):646-55 - PubMed
  24. J Clin Oncol. 1999 Mar;17(3):958-67 - PubMed
  25. J Clin Oncol. 1997 Sep;15(9):3156-63 - PubMed
  26. J Clin Oncol. 2002 Dec 1;20(23):4567-73 - PubMed
  27. Semin Oncol. 2001 Aug;28(4 Suppl 15):16-21 - PubMed
  28. Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1243-52 - PubMed
  29. N Engl J Med. 1989 Aug 17;321(7):419-24 - PubMed
  30. N Engl J Med. 1997 Jul 31;337(5):295-300 - PubMed

Publication Types